Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9713884 | 0.87 | PKM (0.55) | ALDH1A1L3MBTL1PKMTSHRTDP1 | |
| SCHEMBL9714054 | 0.86 | PKM (0.54) | ALDH1A1L3MBTL1PKMMAPTLMNA | |
| SCHEMBL9713911 | 0.84 | PKM (0.52) | ALDH1A1L3MBTL1PKMTDP1MAPT | |
| SCHEMBL9714057 | 0.81 | PKM (0.48) | ALDH1A1L3MBTL1PKMMAPTLMNA | |
| SCHEMBL12677894 | 0.78 | TSHR (0.73) | ALDH1A1L3MBTL1PKMTSHRTDP1 | |
| SCHEMBL23620238 | 0.75 | PKM (1.00) | ALDH1A1PKMTDP1MAPTLMNA | |
| SCHEMBL6269491 | 0.75 | ALDH1A1 (1.00) | ALDH1A1L3MBTL1TSHRTDP1MAPT | |
| SCHEMBL12012375 | 0.73 | TSHR (1.00) | ALDH1A1L3MBTL1TSHRTDP1MAPT | |
| SCHEMBL9714041 | 0.73 | ALDH1A1 (0.56) | ALDH1A1PKMMAPTLMNAGAA | |
| SCHEMBL9713804 | 0.73 | GAA (0.53) | ALDH1A1L3MBTL1PKMTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8692001-B2 | Sulfonamides for the modulation of PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2014-04-08 | — | — | US | disclosed |
| US-8692001-B2 | Sulfonamides for the modulation of PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2014-04-08 | — | — | US | disclosed |
| WO-2012056319-A1 | SULFONAMIDES FOR THE MODULATION OF PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-05-03 | — | — | WO | disclosed |
| US-20120108631-A1 | Sulfonamides for the Modulation of PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-05-03 | — | — | US | disclosed |
| US-20120108631-A1 | Sulfonamides for the Modulation of PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-05-03 | — | — | US | disclosed |
| US-5084449-A | Bactericides and antiprotozoa agents | DR. KARL THOMAE GMBH (DE) | 1992-01-28 | — | — | US | disclosed |
| US-4992430-A | Anti-bacterial compositions comprising a substituted bis-(4-aminophenyl)-sulfone and a dihydro-folic acid reductase | DR. KARL THOMAE GMBH (DE) | 1991-02-12 | — | — | US | disclosed |
| US-4829058-A | INHIBITORS OF BACTERIA, MYCOBACTERIA AND PLASMODIA | DR. KARL THOMAE GMBH (DE) | 1989-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108631-A1 | Sulfonamides for the Modulation of PKM2 | PDK1, PDK4, PDK2 | ALDH1A1 2275/4885L3MBTL1 2986/4885PKM 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.